Egyptian asthma study reveals steroid reliance
NCT ID NCT06283290
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study measured how often people with severe asthma in Egypt use oral corticosteroids (OCS), a common but strong medication. Researchers looked at 201 patients across multiple clinics to understand treatment patterns and asthma types. The goal was to gather information, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
201 people
The number who actually took part.
- Started
-
Mar 2024
- Finished
-
Nov 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will include patients 18 years and older with severe asthma, per the definition of the GINA 2022 Guidelines \[4\]. Patients will be identified and invited to participate in the study consecutively as they attend their routine clinical visits at the included centers. To be included in the study, each patient should meet all the inclusion criteria and none of the exclusion criteria described in the sections below. In addition, patients should provide written, informed consent prior to any study-specific procedures or data collection. The enrolment period will be approximately 8 months or until the required number of patients has been included, whichever occurs first.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female patient, aged 18 years or older by the time of study entry * Patient visiting a participating center for a routine clinical appointment * The patient is willing and able to provide a blood sample for IgE and eosinophil levels determination as part of their routine clinical visit * Patients with a diagnosis of severe asthma for at least one year as defined by: Treatment with guidelines-suggested medications for Global Initiative for Asthma (3) steps 4-5 asthma * Patients (or their legal guardian) who voluntarily sign and date the informed consent form (ICF) prior to study entry Exclusion Criteria: * Patients with a diagnosis of chronic obstructive pulmonary disease (COPD) or other chronic respiratory conditions beyond severe asthma * An acute or chronic condition that, by the investigator's decision, would limit the patient's ability to participate in this study * Patients who are currently under biologic therapy to treat their severe asthma
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Severe asthma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Dakahlia, Dakahlia Governorate, Egypt
-
Research Site
Sharkia, Sharqia Province, Egypt
-
Research Site
Alexandria, Egypt
-
Research Site
Cairo, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single injection tame severe asthma in fungal allergy?
- Could a simple exercise programme boost asthma remission?
- A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
- Could a biologic drug free severe asthma patients from High-Dose steroids?
- Scientists probe why tezepelumab doesn't stop all asthma attacks
- Smart inhalers track Fasenra's asthma control over full dosing cycle